

Pinar Kilic-Rueger Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim Am Rhein GERMANY

23.09.2024 nr RKU-4/72

## **DECISION**

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor Boehringer Ingelheim International GmbH on 19.08.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99<sup>1</sup> (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99<sup>6</sup> section 1 p 1 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no 1305-0023 under the following conditions:

protocol no: 1305-0023 (Version 4, dated September 21, 2023)

**full title of the trial**: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

sponsor of the trial: Boehringer Ingelheim International GmbH

number of subjects in Estonia: 1

## principal investigators and study locations:

- Dr Martti Jaanus, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk Director General